Martin Sarter Selected Research

Cognitive Dysfunction

1/2022	Disrupted Choline Clearance and Sustained Acetylcholine Release In Vivo by a Common Choline Transporter Coding Variant Associated with Poor Attentional Control in Humans.
8/2019	Repetitive mild concussion in subjects with a vulnerable cholinergic system: Lasting cholinergic-attentional impairments in CHT+/- mice.
7/2014	A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats.
2/2013	The presynaptic choline transporter imposes limits on sustained cortical acetylcholine release and attention.
1/2011	Modes and models of forebrain cholinergic neuromodulation of cognition.
1/2009	A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.
1/2009	Phasic acetylcholine release and the volume transmission hypothesis: time to move on.
1/2008	Cholinergic mediation of attention: contributions of phasic and tonic increases in prefrontal cholinergic activity.
10/2007	Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats.
7/2007	Abnormal neurotransmitter release underlying behavioral and cognitive disorders: toward concepts of dynamic and function-specific dysregulation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Sarter Research Topics

Disease

15	Schizophrenia (Dementia Praecox) 01/2016 - 05/2002
14	Parkinson Disease (Parkinson's Disease) 01/2022 - 10/2013
14	Cognitive Dysfunction 01/2022 - 09/2002
8	Neurobehavioral Manifestations 07/2014 - 10/2007
2	Movement Disorders (Movement Disorder) 01/2021 - 06/2019
2	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 10/2004
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2008 - 07/2007
1	Brain Concussion (Cerebral Concussion) 08/2019
1	Traumatic Brain Injuries (Traumatic Brain Injury) 08/2019
1	Wounds and Injuries (Trauma) 08/2019
1	Substance-Related Disorders (Drug Abuse) 01/2018
1	Neuroinflammatory Diseases 09/2017
1	Mood Disorders (Mood Disorder) 12/2013
1	Brain Diseases (Brain Disorder) 11/2013
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 02/2013
1	Gliosis 06/2005
1	Infarction (Infarctions) 06/2005
1	Ischemia 06/2005
1	Embolism (Embolus) 06/2005

Drug/Important Bio-Agent (IBA)

29	Cholinergic Agents (Cholinergics)IBA 01/2022 - 09/2002
4	choline transporterIBA 01/2022 - 02/2013
4	Pharmaceutical PreparationsIBA 01/2009 - 05/2002
3	(2- (6- fluoro- 1H- indol- 3- yl)- ethyl)- (3- (2,2,3,3- tetrafluoropropoxy)benzyl)amineIBA 01/2020 - 01/2017
3	Levodopa (L Dopa)FDA LinkGeneric 01/2017 - 10/2013
2	Cholinergic ReceptorsIBA 01/2021 - 01/2011
2	Dopamine (Intropin)FDA LinkGeneric 01/2020 - 04/2015
2	Rivastigmine (Exelon)FDA LinkGeneric 01/2020 - 06/2019
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2017 - 01/2011
2	Biomarkers (Surrogate Marker)IBA 03/2013 - 01/2012
2	Clozapine (Clozaril)FDA LinkGeneric 12/2009 - 10/2008
2	Amphetamine (Amfetamine)FDA LinkGeneric 10/2007 - 05/2002
1	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2022
1	Proteins (Proteins, Gene)FDA Link 09/2017
1	serotonin 6 receptorIBA 01/2017
1	Donepezil (Aricept)FDA LinkGeneric 01/2017
1	kynurenine-oxoglutarate transaminaseIBA 07/2014
1	KynurenineIBA 07/2014
1	EnzymesIBA 07/2014
1	PF-04859989IBA 07/2014
1	Glutamic Acid (Glutamate)FDA Link 07/2014
1	3- (3- (pyridine- 3- yl)- 1,2,4- oxadiazol- 5- yl)benzonitrileIBA 11/2013
1	Choline (Choline Chloride)IBA 02/2013
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2011
1	N-Methylaspartate (NMDA)IBA 12/2009
1	Haloperidol (Haldol)FDA LinkGeneric 10/2008
1	Antipsychotic Agents (Antipsychotics)IBA 09/2007
1	Therapeutic UsesIBA 09/2007
1	Neurotransmitter Agents (Neurotransmitter)IBA 07/2007
1	Glial Fibrillary Acidic ProteinIBA 06/2005
1	fluoro jadeIBA 06/2005
1	Ketamine FDA LinkGeneric 05/2002

Therapy/Procedure

1	Home Nursing (Nursing, Home) 01/2020
1	Therapeutics 01/2020
1	Denervation 01/2017
1	Long-Term Care 01/2017
1	Institutionalization (Institutionalized Persons) 07/2014
1	Injections 06/2005
1	Microspheres (Microsphere) 06/2005